Application of combination of cytokine and hypoglycemic in treatment of diabetes

Abstract

The invention discloses the use of combination of cytokine and hypoglycemic in treatment of diabetes, wherein on the basis of using conventional hypoglycemic medicament for diabetes treatment, bone marrow hemapoietic stem cell mobilizing agent-recombinant human granular leukocyte colony stimulating factor (GCSF) is integrated, thus the damaged pancreatic island tissues can be renovated through mobilizing the orthotopic transplantation on pancreatic island positions inside stem cells, and achieving the goal of diabetes treatment.

Description

1 technical field [0001] The invention relates to the application of preparation of medicine for treating diabetes, in particular to the clinical application of cytokine combined with hypoglycemic medicine in treating diabetes and the application in preparation of medicine for treating diabetes. 2. Background technology [0002] Diabetes is an autoimmune disease that is difficult to cure. It is usually treated clinically with subcutaneous injections of insulin hypoglycemic drugs, but the therapeutic effect is not ideal, and it is difficult to prevent the progression and complications of diabetes. Patients need to take drugs for life. [0003] According to the survey results of the 17th International Diabetes Conference in 2000, the number of diabetic patients in the world has exceeded 151 million. In recent years, the incidence of diabetes in various countries has been on the rise. At present, there are mainly three ways to treat diabetes clinically. The first one is the mos...

AI Technical Summary

Problems solved by technology

At present, there are mainly three ways to treat diabetes clinically. The first is the most commonly used subcutaneous injection of insulin to treat type I and some type II diabetes, but practice has proved that its therapeutic effect is not ideal, and it is difficult to prevent the occurrence and development of diabetic complications.

The second method is to implant islet β cells or their substitutes in the human body. This is a very attractive method for diabetic patients who have lost the function of islet cells, but there are insufficient sources of donor cells and immune rejection. The application of this method is limited

[0007] The application of stem cell transplantation to cell replacement therapy for diabetes requires a large number of stem cells to be expanded in vitro. After the cells reach a sufficient number, they are induced to differentiate into pancreatic islet β cells. However, the number of adult tissue stem cells, including pancreatic pluripotent stem cells, is rare. 1. Difficulty in separation; Pancreatic pluripotent stem cells are derived from pancreatic ductal epithelial cells, which are difficult to obtain and cause great shock and damage to the body; in addition, in diabetes, pancreatic islet β cells are destroyed in large numbers and cannot be replenished sufficiently, suggesting that diabetic autologous The source of pancreatic pluripotent stem cells has certain damage; allogeneic pancreatic pluripotent stem cells also face the limitation of limited sources and difficulties in obtaining

Therefore, it is quite difficult to induce differentiation and transplantation of pancreatic pluripotent stem cells in vitro to treat diabetes.

Moreover, many basic theories of stem cell transplantation have not yet been resolved, and its clinical research application still faces major challenges. First, there are usually very few stem cells in adult tissues and lack of specific markers. Which type of cell transplantation will benefit the most? Secondly, stem cells are directed to differentiate in vitro There are still great defects in the technology, and there are still certain restrictions on the leakage of cells in the process of stem cell transplantation, the purity and quantity of transplanted cells, the location and timing of transplantation, the safety of transplantation and the rejection of the immune system.